Ant International President Highlights AI and Connectivity as Key SME Growth Drivers
12.3.2025 12:19:00 CET | Business Wire | Press release
Artificial Intelligence (AI) is being converted into flexible cross-border payment and digitisation solutions to help SMEs raise efficiency, lowering costs and controlling risks.More industry collaborations are needed to bridge payment systems and tech know-how.
Digital payment innovations are increasingly powerful tools for global businesses to raise productivity and turbocharge growth. The Digital Payment Market size1 is expected to grow at a CAGR of 11.8% and reach US$193.7 billion. However, there are digital divides and silos abound in core financial services for the global commerce system, especially in cross-border online and offline digital payment and settlement.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250312187829/en/

Douglas Feagin (left), President of Ant International, discussed payments innovation at GFTN Forum Japan in March 2025. (Photo: Business Wire)
“Even as technology advances in leaps and bounds, small businesses continue to face challenges in today’s digitised international transactions, from cross-border payment to cross-market growth,” said Douglas Feagin, President of Ant International, during the GFTN Forum held during the Japan Fintech Festival in Japan in March 2025. “We need to convert exciting developments in foundational technologies, such as AI, into comprehensive, effective and affordable solutions for the world’s long-tail business community.”
Ant International’s flagship Alipay+ cross-border mobile payment and digitisation technology has expanded to support 36 international payment apps, connecting over 90 million merchants across 66 markets. This “invisible” technology behind the cash register enables merchants to receive cross-border payments seamlessly and securely from individuals using their home e-wallets while maintaining competitive foreign exchange rates.
Interoperability is key, as local SMEs should be able to accept international payments more easily. In Asia, initiatives like national QRs have greatly boosted connectivity, and Alipay+ helps to bridge these infrastructures with our global payment partner users, but more needs to be done to bring together card and wallet-based ecosystems, Feagin said.
For SMEs, the capacity to accept various forms of international payments is not merely an advantage; it has become an essential factor for survival and growth in an increasingly competitive marketplace, Feagin noted.
Artificial Intelligence (AI) technology is crucial in addressing these pressing needs by providing tools that help SMEs make informed decisions swiftly, ensuring they meet customer demands while minimizing operational risks. A recent McKinsey report2 for 2025 underscores this importance, indicating that 92% of businesses plan to increase their AI investments this year. The consulting firm earlier predicted that companies integrating AI into their financial operations can expect productivity increases of up to 25%3.
At Ant International, AI-powered solutions are being developed to forecast currency demands based on transaction flows, enhancing efficiency in foreign exchange processes and steering the industry towards real-time payment systems.
For instance, Ant International’s AI-driven solution can forecast customers’ foreign-exchange needs with more than 90% accuracy based on provided data, which enables the company to help customers optimise their FX strategies.
As financial fraud becomes increasingly sophisticated, AI is paramount in safeguarding transactions. Ant International’s AI-powered risk management capabilities can effectively implement advanced fraud detection mechanisms that analyse patterns, identify anomalies, and protect against potential threats.
Interoperability will continue to be enhanced, particularly in Asia, where national QR systems and mobile wallets facilitate seamless transactions. This trend is expected to evolve rapidly as new LLM models are developed, enabling companies to streamline these workflows, said Feagin.
“We expect this revolution to continue at a rapid pace, and AI to accelerate efficiency and provide solutions for our customers,” added Feagin.
1https://www.marketsandmarkets.com/Market-Reports/digital-payment-market-209834053.html
2https://www.mckinsey.com/capabilities/mckinsey-digital/our-insights/superagency-in-the-workplace-empowering-people-to-unlock-ais-full-potential-at-work
3https://psico-smart.com/en/blogs/blog-how-can-artificial-intelligence-enhance-productivity-management-in-the-workplace-88579
View source version on businesswire.com: https://www.businesswire.com/news/home/20250312187829/en/


Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom